# Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

> **NCT01008150** · PHASE2 · COMPLETED · sponsor: **NSABP Foundation Inc** · enrollment: 141 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** Neratinib
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01008150
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-09
- **Final completion:** 2016-11-25
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2021-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01008150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01008150, "Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01008150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*